Previous close | 10.55 |
Open | 10.55 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 4.00 |
Expiry date | 2026-01-16 |
Day's range | 10.55 - 10.55 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Teva stock surged Wednesday after the company beat first-quarter views and unveiled promising results from its schizophrenia drug study.
Shares of Teva Pharmaceutical Industries were climbing yet again on Wednesday, after the company announced positive results in a trial of a schizophrenia medicine. Its quarterly results, also disclosed early Wednesday, were mixed. Revenue was $3.8 billion for the quarter, slightly better than the FactSet consensus estimate of $3.7 billion, while non-GAAP diluted earnings were 48 cents a share.
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.